<SEC-DOCUMENT>0001004878-17-000254.txt : 20171212
<SEC-HEADER>0001004878-17-000254.hdr.sgml : 20171212
<ACCEPTANCE-DATETIME>20171212125759
ACCESSION NUMBER:		0001004878-17-000254
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171207
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171212
DATE AS OF CHANGE:		20171212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		171251349

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k801prsrls12-17.txt
<DESCRIPTION>8-K ITEM 8..01
<TEXT>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (date of earliest event reported): December 7, 2017

                               CEL-SCI CORPORATION
                       ----------------------------------
             (Exact name of Registrant as specified in its charter)

          Colorado                      01-11889                 84-0916344
 ---------------------------        -----------------        -----------------
(State or other jurisdiction      (Commission File No.)     (IRS Employer
of incorporation)                                            Identification No.)

                         8229 Boone Boulevard, Suite 802
                             Vienna, Virginia 22182
                       ----------------------------------
          (Address of principal executive offices, including Zip Code)

       Registrant's telephone number, including area code: (703) 506-9460

                                       N/A
                       ----------------------------------
          (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy  the filing  obligation  of the  registrant  under any of the  following
provisions (see General Instruction A.2. below)

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
    CFR 240.14a-12)

[ ] Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement  communications  pursuant to Rule 13e-14(c) under the
    Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the  registrant is an emerging  growth company as
defined in Rule 405 of the Securities  Act of 1933  (ss.203.405 of this chapter)
or Rule  12b-2 of the  Securities  Exchange  Act of 1934  (ss.204.12b-2  of this
chapter.

Emerging growth company [ ]

If an emerging  growth  company,  indicate by check mark if the  registrant  has
elected not to use the extended  transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. [ ]

                                       1
<PAGE>

Item 8.01   Other Events

     On December 7, 2017, the Company  issued a press release,  filed as Exhibit
99.1,  concerning the  observations  and  recommendations  the Independent  Data
Monitoring Committee (IDMC) for the Company's Phase 3 head and neck cancer study
of Multikine.

     The IDMC:

      a) saw no evidence of any significant safety questions, and

      b) recommended that the Company continue the study.

     On December 11, 2017, the Company issued a press release,  filed as Exhibit
99.2, announcing that no further enrollment was required for the Company's Phase
3 head and neck cancer study of Multikine.

Item 9.01  Exhibits

Exhibit
Number     Description of Document
------     -----------------------

  99.1     December 7, 2017 press release

 99.2      December 11, 2017 press release



                                       2
<PAGE>


                                   SIGNATURES


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date:  December 12, 2017

                               CEL-SCI CORPORATION


                                       By: /s/ Patricia B. Prichep
                                           -----------------------------------
                                          Patricia B. Prichep
                                          Senior Vice President of Operations
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>form8k801ex991dec-17.txt
<DESCRIPTION>EXHIBIT 99.1
<TEXT>





                                  EXHIBIT 99.1




<PAGE>



8229 Boone Boulevard, Suite 802                              COMPANY CONTACT:
Vienna, VA  22182.  placecountry-regionUSA                   Gavin de Windt
Telephone (703) 506-9460                                     CEL-SCI Corporation
www.cel-sci.com                                              (703) 506-9460

      CEL-SCI REPORTS RECENT DATA REVIEW BY THE INDEPENDENT DATA MONITORING
          COMMITTEE FOR ITS PIVOTAL PHASE 3 HEAD AND NECK CANCER STUDY

VIENNA,  VA,  December  7, 2017 --  CEL-SCI  Corporation  (NYSE  American:  CVM)
announced today that the Independent  Data Monitoring  Committee  (IDMC) for the
Company's  pivotal  Phase 3 head and neck  cancer  study of its  investigational
immunotherapy  Multikine* (Leukocyte  Interleukin,  Injection) has completed its
review of the Phase 3 study data.  The data from all 928 enrolled  patients were
provided to the IDMC by the clinical research organization (CRO) responsible for
data management of this Phase 3 study.

The IDMC made the following observation and recommendation:

      a) The IDMC saw no evidence of any significant safety questions.

      b) The IDMC recommends continuing the study.


IDMCs are committees commonly used by sponsors of clinical trials to protect the
interests of the patients and the integrity of the study data in ongoing trials,
especially when the trials involve patients with life threatening diseases,  and
when, as in cancer clinical trials, they extend over long periods of time. About
CEL-SCI Corporation

CEL-SCI  is a Phase 3 cancer  immunotherapy  company.  When it  comes to  cancer
immunotherapy, CEL-SCI believes it is most logical to boost the patient's immune
system while it is still intact in order to have the greatest possible impact on
survival.  Therefore,  CEL-SCI treats patients who are newly diagnosed with head
and neck cancer with its lead investigational  immunotherapy  Multikine,  BEFORE
they have received  surgery,  radiation  and/or  chemotherapy.  This approach is
unique.  Most other  cancer  immunotherapies  are used only  after  conventional
therapies have been tried and/or failed.  Head and neck cancer  represents about
6% of all cancers.  Multikine has received Orphan Drug  designation from the FDA
for the treatment of head and neck cancer  patients with advanced  squamous cell
carcinoma.

The Company's LEAPS  technology is being developed as a therapeutic  vaccine for
rheumatoid  arthritis and is supported by grants from the National Institutes of
Health. CEL-SCI has patents on Multikine from the US, Europe, China, and Japan.

The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

                                       1
<PAGE>

Forward-Looking Statements

This press release  contains  forward-looking  statements  within the meaning of
Section 27A of the  Securities  Act of 1933, as amended,  and Section 21E of the
Securities  Exchange Act of 1934, as amended.  When used in this press  release,
the words  "intends,"  "believes,"  "anticipated,"  "plans" and  "expects,"  and
similar expressions,  are intended to identify forward-looking  statements. Such
statements  are  subject  to risks and  uncertainties  that could  cause  actual
results to differ  materially from those projected.  Factors that could cause or
contribute to such differences  include,  an inability to duplicate the clinical
results  demonstrated in clinical studies,  timely  development of any potential
products  that  can be  shown  to be safe  and  effective,  receiving  necessary
regulatory  approvals,  difficulties  in  manufacturing  any  of  the  Company's
potential  products,  inability  to raise  the  necessary  capital  and the risk
factors set forth from time to time in CEL-SCI's filings with the Securities and
Exchange  Commission,  including  but not limited to its report on Form 10-K and
10-K/A  for the year  ended  September  30,  2016.  The  Company  undertakes  no
obligation   to  publicly   release   the  result  of  any   revision  to  these
forward-looking   statements  which  may  be  made  to  reflect  the  events  or
circumstances   after  the  date  hereof  or  to  reflect  the   occurrence   of
unanticipated events.

* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has
registered  for  this  investigational  therapy,  and this  proprietary  name is
subject  to FDA  review in  connection  with the  Company's  future  anticipated
regulatory submission for approval.  Multikine has not been licensed or approved
for  sale,  barter  or  exchange  by the  FDA or any  other  regulatory  agency.
Similarly,  its  safety  or  efficacy  has not  been  established  for any  use.
Moreover,  no  definitive   conclusions  can  be  drawn  from  the  early-phase,
clinical-trials  data involving the investigational  therapy Multikine.  Further
research is required,  and early-phase  clinical trial results must be confirmed
in the  Phase 3  clinical  trial  of  this  investigational  therapy  that is in
progress.
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>form8k801ex992dec-17.txt
<DESCRIPTION>EXHIBIT 99.2
<TEXT>




                                  EXHIBIT 99.2




<PAGE>


8229 Boone Boulevard, Suite 802                              COMPANY CONTACT:
Vienna, VA  22182.  placecountry-regionUSA                   Gavin de Windt
Telephone (703) 506-9460                                     CEL-SCI Corporation
www.cel-sci.com                                              (703) 506-9460

  CEL-SCI REACHES FULL ENROLLMENT IN PIVOTAL PHASE 3 HEAD AND NECK CANCER STUDY

 Major Milestone Achieved in World's Largest Head and Neck Cancer Phase 3 Study

VIENNA,  VA,  December  11, 2017 -- CEL-SCI  Corporation  (NYSE  American:  CVM)
announced  today that no further  patient  enrollment is required in the pivotal
Phase  3  head  and  neck  cancer  study  of its  investigational  immunotherapy
Multikine* (Leukocyte Interleukin,  Injection). The accrual and treatment phases
of this Phase 3 study are  complete.  All of the 928  enrolled  patients  in the
study are being followed-up as required by the study protocol.

CEL-SCI  recently  announced  that  the  study's   Independent  Data  Monitoring
Committee  (IDMC)  completed  its most  recent  review  of the data from all 928
patients  enrolled in the study,  and recommended  continuing the study as there
was no evidence of any significant safety questions.

The primary  endpoint of the study, a 10% improvement in overall survival of the
Multikine  treatment  regimen plus  Standard of Care (SOC) vs.  Standard of Care
alone, will be determined after a total of 298 deaths have occurred in these two
main  comparator arms of the study and have been recorded in the study database.
The last patient was enrolled in the study in September 2016.  Approximately 135
patients were  enrolled in the study from 2011 to 2013,  about 195 were enrolled
in 2014, about 340 in 2015, and about 260 in 2016. The study protocol assumed an
overall survival rate of about 55% at 3 years for the SOC treatment group alone.

IDMCs are committees commonly used by sponsors of clinical trials to protect the
interests of the patients and the integrity of the study data in ongoing trials,
especially when the trials involve patients with life threatening diseases,  and
when, as in cancer clinical trials, they extend over long periods of time.

About CEL-SCI Corporation

CEL-SCI  is a Phase 3 cancer  immunotherapy  company.  When it  comes to  cancer
immunotherapy, CEL-SCI believes it is most logical to boost the patient's immune
system while it is still intact in order to have the greatest possible impact on
survival.  Therefore,  CEL-SCI treats patients who are newly diagnosed with head
and neck cancer with  Multikine  BEFORE they have  received  surgery,  radiation
and/or chemotherapy.  This approach is unique. Most other cancer immunotherapies

                                       1
<PAGE>

are used only after conventional  therapies have been tried and/or failed.  Head
and neck cancer  represents  about 6% of all  cancers.  Multikine  has  received
Orphan Drug  designation  from the FDA for the treatment of head and neck cancer
patients with advanced squamous cell carcinoma.

The Company's LEAPS  technology is being developed as a therapeutic  vaccine for
rheumatoid  arthritis and is supported by grants from the National Institutes of
Health.  CEL-SCI has patents on  Multikine  from the U.S.,  Europe,  China,  and
Japan.

The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

Forward-Looking Statements

This press release  contains  forward-looking  statements  within the meaning of
Section 27A of the  Securities  Act of 1933, as amended,  and Section 21E of the
Securities  Exchange Act of 1934, as amended.  When used in this press  release,
the words  "intends,"  "believes,"  "anticipated,"  "plans" and  "expects,"  and
similar expressions,  are intended to identify forward-looking  statements. Such
statements  are  subject  to risks and  uncertainties  that could  cause  actual
results to differ  materially from those projected.  Factors that could cause or
contribute to such differences  include,  an inability to duplicate the clinical
results  demonstrated in clinical studies,  timely  development of any potential
products  that  can be  shown  to be safe  and  effective,  receiving  necessary
regulatory  approvals,  difficulties  in  manufacturing  any  of  the  Company's
potential  products,  inability  to raise  the  necessary  capital  and the risk
factors set forth from time to time in CEL-SCI's filings with the Securities and
Exchange  Commission,  including  but not limited to its report on Form 10-K and
10-K/A  for the year  ended  September  30,  2016.  The  Company  undertakes  no
obligation   to  publicly   release   the  result  of  any   revision  to  these
forward-looking   statements  which  may  be  made  to  reflect  the  events  or
circumstances   after  the  date  hereof  or  to  reflect  the   occurrence   of
unanticipated events.

* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has
registered  for  this  investigational  therapy,  and this  proprietary  name is
subject  to FDA  review in  connection  with the  Company's  future  anticipated
regulatory submission for approval.  Multikine has not been licensed or approved
for  sale,  barter  or  exchange  by the  FDA or any  other  regulatory  agency.
Similarly,  its  safety  or  efficacy  has not  been  established  for any  use.
Moreover,  no  definitive   conclusions  can  be  drawn  from  the  early-phase,
clinical-trials  data involving the investigational  therapy Multikine.  Further
research is required,  and early-phase  clinical trial results must be confirmed
in the  Phase 3  clinical  trial  of  this  investigational  therapy  that is in
progress.
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
